Hyperinsulinemic Hypoglycemia
Conditions
Brief summary
The purpose of the study is to evaluate the effectiveness of exenatide in adults experiencing episodes of hyperinsulinemic hypoglycemia following Roux-en-Y bariatric surgery.
Detailed description
Roux-en-Y gastric bypass surgery (RYGB) is one of the most common bariatric surgeries in the United States and is generally highly effective for weight loss. Unfortunately, among the potential complications is hyperinsulinemic hypoglycemia. Though the prevalence of this disorder has not been fully characterized, it can be associated with debilitating symptoms which severely impact quality of life and can be life-threatening. The underlying pathophysiology of hyperinsulinemic hypoglycemia likely involves a mismatch in the amount of insulin secreted in response to mealtime carbohydrate absorption. It has been observed that the ingestion of a high carbohydrate load often leads to a modest rise in post-prandial glucose levels followed by an inappropriately exaggerated insulin release among individuals with this condition. Low carbohydrate diet sometimes provides full or partial relief of the symptoms. Standard medical management for RYGB associated postprandial hyperinsulinemic hypoglycemia includes acarbose, which partially reduces carbohydrate absorption from the gut, and diazoxide, which directly inhibits insulin release from pancreatic beta cells. However, the medical options are not reliably effective, leading some individuals to reverse RYGB, which also may not be effective, or even undergo partial pancreatectomy, risking additional complications such as diabetes. Much more reliably effective treatments are needed for this special population who develop this bariatric surgical complication. Potential mechanisms contributing to the mismatched insulin secretion post RYGB include decreased systemic and adipose tissue inflammation, and increased insulin receptor expression in liver and skeletal muscle, and increases in adiponectin.
Interventions
DRUGExenatide
Exenatide at a dose of 5 mcg
DRUGAcarbose
Acarbose at a dose of 25 mg
Placebo for Exenatide
DRUGAcarbose Placebo
Placebo for Acarbose
Sponsors
University of Minnesota
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. must have undergone RYGB and subsequently developed post-prandial hypoglycemia (defined as at least 3 episodes over a six-month period with documented capillary blood sugars \[\<60 mg/dL with hypoglycemic symptoms). Subjects may also have had a formal mixed meal tolerance test with post meal blood sugar \<60 mg/dL. 2. Subjects who otherwise meet the study criteria above with hypoglycemia symptoms but who do not have documented hypoglycemia by plasma measurement may undergo a screening visit to document the requisite levels for consideration into the study.
Exclusion criteria
1. Chronic or acute diseases of the liver. 2. Chronic or acute diseases of the pancreas (including type 1 diabetes or pancreatitis or a history of pancreatitis). Subjects may have a diagnosis of type 2 diabetes but must no longer require diabetes medication. 3. Chronic or acute diseases of the kidneys. 4. Known malignancies and must not have a family history of medullary thyroid cancer. 5. History of pre-RYGB hypoglycemia symptoms or low documented plasma glucose preoperatively. 6. Pregnant or plans to become pregnant throughout study duration 7. Breastfeeding 8. Medication exclusions in addition to the current use of diabetes medications. Subjects will be excluded if they have previously taken GLP-1 agonists.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Glucose area under the curve (AUC) following treatment for each 4-hour test period | During the 4-hour test period | Each time point (15, 30, 45, 60, 90, 120, 180 and 240 minutes) will be used to calculate AUC using the trapezoidal method. |
| Presence of hypoglycemia | 15, 30, 45, 60, 90, 120, 180 and 240 minutes | If at each time-point (15, 30, 45, 60, 90, 120, 180 and 240 minutes) plasma glucose is \<60 mg/dL, participants will be defined as hypoglycemic |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Minimum post-prandial blood sugar level (mg/dL) | post meal test | The lowest post-prandial blood glucose level at any time point (15, 30, 45, 60, 90, 120, 180 and 240 minutes) may be used as the minimum post-prandial blood sugar level (mg/dL). |
| Change in post-prandial blood glucose from 0min to 120min | 0min to 120min | % change in blood glucose 0min to 120min |
| Change in post-prandial Insulin levels (mcg/mL) | 0min to 120min | % change in insulin 0min to 120min |
Countries
United States
Outcome results
None listed